Quintrio
Home

ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS

Neuraxis, Inc.

NRXS

Neuraxis Inc is a growth-stage medical technology company focused on neuromodulation therapies for chronic and debilitating conditions in the gastrointestinal (GI) digestive system, specifically from disorders of the gut-brain interaction (DGBIs) in pediatrics and adults. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).

Last trade $4.75
Day change -$0.05 (-1.04%)
Day range $4.51 – $4.92
Volume 150,896
Market cap $68M

Open XASE

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$68.13M
Price / earnings
—
Price / book
18.81×
Price / sales
10.43×
EV / sales
9.78×
EV / EBITDA
-5.28×

Profitability

Earnings per share
-$0.91
Return on assets
-193.4%
Return on equity
-355.31%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0.06×
Current ratio
2.1×
Quick ratio
2.01×
Cash ratio
1.55×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$6.47M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for NRXS, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$2.03M$1.93M$1.61M$968.13K$811.41K$894.09K$895.66K$761.17K
Cost of revenue$271.66K$272.57K$218.37K$141.65K$135.49K$146.64K$139.48K$105.05K
Gross profit$1.76M$1.66M$1.39M$826.48K$675.93K$747.44K$756.18K$656.11K
Selling, general and administrative$8.05M$3.51M$3.03M$2.4M$2.65M$2.35M$2.93M$1.98M
Research and development$288.75K$274.34K$99.57K$146.18K$130.85K$115.2K$117.87K$138.43K
Total operating expenses$8.34M$3.78M$3.13M$2.54M$2.78M$2.47M$3.05M$2.12M
Operating income-$6.58M-$2.12M-$1.74M-$1.72M-$2.1M-$1.72M-$2.3M-$1.47M
Interest expense-$20.13K-$19.79K-$26.19K-$28.64K-$29.66K-$13.43K-$2.24K-$2.39K
Income before taxes-$6.55M-$2.09M-$1.76M-$1.71M-$2.12M-$1.69M-$2.28M-$1.45M
Income taxes$0$0$0$0$0$0$0$0
Net income-$6.55M-$2.09M-$1.76M-$1.71M-$2.12M-$1.69M-$2.28M-$1.45M
Net income attributable to common shareholders-$6.74M-$2.28M-$1.95M-$1.9M-$2.32M-$1.9M-$2.49M-$1.61M
EBITDA-$6.56M-$2.11M-$1.72M-$1.69M-$2.08M-$1.7M-$2.29M-$1.46M
Basic earnings per share-$0.52-$0.19-$0.18-$0.18-$0.24-$0.22-$0.33-$0.23
Diluted earnings per share-$0.52-$0.19-$0.18-$0.18-$0.24-$0.22-$0.33-$0.23

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

Doximity (DOCS) Beats Q2 Earnings and Revenue Estimates

Doximity reported Q3 2026 earnings of $0.36 per share, beating consensus estimates of $0.34, with revenues of $174.54 million exceeding expectations by 2.27%. However, the stock has declined 21.7% year-to-date compared to the S&P 500's 12.3% gain. The company received a Zacks Rank #3 (Hold) rating with mixed estimate revisions, suggesting near-term performance in line with the market.

Zacks Investment Research

Is Kodak having a "Kodak moment?" 2 watchlist stocks.

Eastman Kodak (KODK) shows operational improvement with 18% revenue growth and expanding margins, but analysts maintain a Neutral stance pending consistent FCF execution. NeurAxis (NRXS) demonstrates strong revenue growth and pricing power in neuromodulation products, but high valuation and operating losses keep it on the sidelines at Neutral.

GlobeNewswire Inc.

NeurAxis to Host First Quarter 2026 Results and Business Update Call on Tuesday, May 12, 2026

NeurAxis, Inc. (NYSE American: NRXS), a medical technology company specializing in neuromodulation therapies, announced it will report Q1 2026 financial results on May 12, 2026, before market open, followed by a conference call at 9:00 am ET. The company commercializes IB-Stim, its proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, which is FDA cleared for treating functional abdominal pain associated with IBS and functional dyspepsia in patients 8 years and older.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.